TIGAR is amplified in different cancer types and its down-regulation sensitizes cancer cells to PARP inhibitors through inhibition of the pentose phosphate pathway, increase in ROS and DNA damage, down-regulation of BRCA1/2 and RAD51, and induction of cellular senescence (Fang et al. 2019a). The gene discussed is PARP1; the disease is cancer.